In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Women with angina and no obstructive coronary artery disease have reduced myocardial perfusion reserve assessed with cardiac computed tomography perfusion

Session Poster Session 2

Speaker Daria Frestad

Event : ESC Congress 2018

  • Topic : imaging
  • Sub-topic : CT Myocardial Perfusion
  • Session type : Poster Session

Authors : DF Bechsgaard (Copenhagen,DK), I Gustafsson (Copenhagen,DK), MM Michelsen (Copenhagen,DK), ND Mygind (Copenhagen,DK), A Pena (Copenhagen,DK), KF Raft (Copenhagen,DK), J Linde (Copenhagen,DK), KF Kofoed (Copenhagen,DK), E Prescott (Copenhagen,DK), JD Hove (Copenhagen,DK)

Authors:
D.F. Bechsgaard1 , I. Gustafsson1 , M.M. Michelsen2 , N.D. Mygind3 , A. Pena4 , K.F. Raft2 , J. Linde3 , K.F. Kofoed3 , E. Prescott2 , J.D. Hove1 , 1Hvidovre UniversityHospital, Cardiology - Copenhagen - Denmark , 2Bispebjerg University Hospital, Cardiology - Copenhagen - Denmark , 3Rigshospitalet - Copenhagen University Hospital, Cardiology - Copenhagen - Denmark , 4Gentofte University Hospital, Cardiology - Copenhagen - Denmark ,

On behalf: the iPOWER study group

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 370

Background: In the absence of obstructive coronary disease (<50% diameter stenosis; NOCAD), coronary microvascular dysfunction, manifested as reduced ability to increase myocardial perfusion with increasing oxygen demand, is the possible explanation for recurrent angina and adverse cardiovascular prognosis. We hypothesized that symptomatic women with NOCAD have reduced myocardial perfusion reserve (MPR) evaluated with cardiac computed tomography (CT) perfusion (CTP) compared to healthy sex-matched reference population.

Methods: We included women with angina and NOCAD on invasive coronary angiography (cases; n=109) and a sex-matched reference population (controls; n=34) without history of angina, coronary heart disease, and NOCAD on coronary CT angiography. A semi-quantitative assessment of MPR, defined as the relative difference of perfusion before and after adenosine-induced vasodilation, was performed by static CTP.

Results: Cases were on average 4 years older (p=0.04) and had a higher burden of risk factors (2±1 vs. 1±1; p<0.001). Cases showed a tendency towards higher basal perfusion and lower hyperemic perfusion, compared to controls. The ability to increase global and regional myocardial perfusion during adenosine-induced vasodilation was significantly lower in cases compared to controls (Table). This remained unchanged when adjusting for age, risk factors and presence of coronary atheromatosis.

Conclusion: Women with angina and NOCAD have impaired microvascular function, manifested as reduced MPR.

Global and regional myocardial perfusio

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are